Editorial
Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S183-S186
.
(26 September 2018)
Osimertinib in first line setting: preventive or delayed T790M occurrence?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S187-S190
.
(26 September 2018)
COX-2 inhibitors in NSCLC: never-ending story or misplaced?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S191-S194
.
(26 September 2018)
Is more the better?—cetuximab in non-small cell lung cancer patients
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S195-S197
.
(26 September 2018)
Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S198-S201
.
(26 September 2018)
A new era of treating advanced lung cancer is upon us
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S202-S205
.
(26 September 2018)
Thymectomy as an oncologic and immunologic treatment
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S206-S207
.
(26 September 2018)
Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S208-S210
.
(26 September 2018)
Immunotherapy efficacy and gender: discovery in precision medicine
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S211-S213
.
(26 September 2018)
Lung cancer and chronic obstructive pulmonary disease: understanding the complexity of carcinogenesis
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S214-S217
.
(26 September 2018)
Identification of a novel therapeutic target in driver-negative nonsmall cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S218-S220
.
(26 September 2018)
Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S221-S224
.
(26 September 2018)
Histology versus cytology: PD-L1 testing in non-small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S225-S227
.
(26 September 2018)
Development of biomarkers for real precision medicine
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S228-S231
.
(26 September 2018)
Intraoperative molecular imaging—a bright navigator for thoracic surgeons in the era of limited resection
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S232-S235
.
(26 September 2018)
The impact of patients’ preferences on the decision of low-dose computed tomography lung cancer screening
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S236-S238
.
(26 September 2018)
LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S239-S242
.
(26 September 2018)
Targeting IL22: a potential therapeutic approach for Kras mutant lung cancer?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S243-S247
.
(26 September 2018)
Studying the immune landscape in lung cancer models: choosing the right experimental tools
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S248-S250
.
(26 September 2018)
Subtype variation and actionability of telomere length abnormality in lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S251-S253
.
(26 September 2018)
Hunting for transcription factors: STAT3 decoy in non-small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S254-S257
.
(26 September 2018)
Thymic tumors with parathymic syndromes: good or bad?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S258-S260
.
(26 September 2018)
Finding paths with the greatest chance of success: enabling and focusing lung cancer screening and cessation in resourceconstrained areas
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S261-S264
.
(26 September 2018)
Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S265-S269
.
(26 September 2018)
Tobacco cessation in lung cancer screening—do we have the evidence?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S270-S274
.
(26 September 2018)
Perspective
Programmed cell death ligand-1 (PD-L1) as a biomarker for nonsmall cell lung cancer (NSCLC) treatment—are we barking up the wrong tree?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S275-S279
.
(26 September 2018)
Letter to the Editor
Dose-escalation of locally advanced non-small cell lung cancer with proton beam therapy
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S280-S282
.
(26 September 2018)
Controversies on Lung Cancer: Pros and Cons2
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S283-S286
.
(26 September 2018)
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S287-S289
.
(26 September 2018)
Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S290-S293
.
(26 September 2018)
Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S294-S296
.
(26 September 2018)
Brief Report
Multidisciplinary quality improvement initiative to standardize reporting of lung cancer screening
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S297-S301
.
(26 September 2018)
Erratum
Erratum: The association between human papillomavirus presence and epidermal growth factor receptor mutations in Asian patients with non-small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S302
.
(26 September 2018)
Erratum to the importance of incorporating smoking cessation into lung cancer screening
Translational Lung Cancer Research
2018;
7
(Suppl 3)
:S303
.
(26 September 2018)
Disclosure:
1. The supplement was published without any sponsorship or funding.
2. The series “Controversies on Lung Cancer: Pros and Cons” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Suresh Senan and Helmut H. Popper served as the unpaid Guest Editors for the series.
